BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Jul 31, 2017
Distillery Therapeutics

Cancer

...colorectal cancer; pancreatic cancer In vitro and cell culture studies identified a hydrazone-based inhibitor of RRM1...
...442 nM, respectively. Next steps include additional preclinical studies of the compound. TARGET/MARKER/PATHWAY: Ribonucleotide reductase M1 (RRM1; R1...
...Chris Godfrey Dealwis, Case Western Reserve University, Cleveland, Ohio email: cxd114@case.edu Claire Quang Case Western Reserve University Ribonucleotide reductase Ribonucleotide reductase M1 (RRM1) (R1)...
BioCentury | Mar 21, 2016
Emerging Company Profile

Targeting toxicity

...do. The molecule interferes with the interaction between ribonucleotide reductase's protein subunits - ribonucleotide reductase M1 (RRM1; R1...
...novel binding pocket on RRM2. Hydroxyurea targets a different binding pocket on RRM2. Gemcitabine targets RRM1...
BioCentury | Jul 23, 2015
Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

...Cardiovascular disease INDICATION: Heart failure Pig studies suggest RRM1 and RRM2 gene therapy could help treat...
...infusion of an adeno-associated virus (AAV) serotype 6 (AAV6) vector encoding the ribonucleotide reductase heterodimers RRM1...
...BioTherapeutics Corp. include conducting a larger preclinical study with human-grade delivery vectors. TARGET/MARKER/PATHWAY: Ribonucleotide reductase M1 (RRM1; R1...
BioCentury | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

...to test the concept in humans. (See "Ace of Hearts," page 5) TARGET/MARKER/PATHWAY: Ribonucleotide reductase M1 (RRM1; R1...
BioCentury | Feb 19, 2015
Targets & Mechanisms

Ace of hearts

...source for myosin than exogenous ATP, and created adeno-associated viral (AAV) vectors to deliver mouse RRM1...
...address those concerns, the first step is to create an AAV-mediated delivery system for human RRM1...
...CD10 ) - neutral endopeptidase ( neprilysin ) RLN2 (H2) - relaxin 2 RRM1 - Ribonucleotide reductase M1...
BioCentury | Feb 13, 2015
Targets & Mechanisms

Ace of hearts

...source for myosin than exogenous ATP, and created adeno-associated viral (AAV) vectors to deliver mouse RRM1...
...address those concerns, the first step is to create an AAV-mediated delivery system for human RRM1...
...CD10 ) - neutral endopeptidase ( neprilysin ) RLN2 (H2) - relaxin 2 RRM1 - Ribonucleotide reductase M1...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
BioCentury | Mar 24, 2014
Company News

Arrowhead, Calando drug delivery, cancer news

Arrowhead said that subsidiary Calando ceased day-to-day operations after it discontinued CALAA-01 for solid tumors - its only internal development program. Calando said data did not support further development of the compound, which had completed a...
BioCentury | Oct 31, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ribonucleotide reductase M2 (RRM2; R2) Cell culture and mouse studies identified RRM2 inhibitors that could help treat drug-resistant cancers. In cancer cell lines resistant...
Items per page:
1 - 10 of 28